Liver transplantation in children with propionic acidaemia - medium term outcomes.
Liver transplantation (LT) for patients with propionic acidaemia (PA) is an emerging therapeutic option. A retrospective review of patients PA with who underwent LT at a tertiary liver centre between 1995 and 2015. Fourteen children were identified (8 males) with median age at initial presentation of 3 days (range 0 - 77). Pre-transplant median protein restriction was 1 g/kg/day (range 0.63 - 1.75), 71% required supportive feeding and 86% had developmental delay. Frequent metabolic decompensations were the main indication for LT with a median age at transplantation of 2.4 years (range 0.8 - 7.1). One graft was from a live and 13 from deceased donors (4 auxiliary). Two-year patient survival was 86% and overall study and graft survival was 79% and 69%, respectively. Three died post LT: at 43 days (biliary peritonitis), 225 days (acute-on-chronic rejection with multi-organ failure) and 13.5 years (post-transplant lymphoproliferative disease). Plasma glycine and propionylcarnitine remain elevated but reduced post-transplant. Of 11 survivors, 5 had at least one episode of acute cellular rejection, 2 sustained a metabolic stroke (with full recovery) and 3 developed mild cardiomyopathy post LT. All have liberalised protein intake and 9 had no further metabolic decompensations [median episodes pre-transplant 4 (range 1 - 30) and post-transplant 0 (range 0 - 5)]. All survivors made some developmental progress post LT and none worsened at a median follow-up of 5.8 years (range 2 - 23). Liver transplantation in PA significantly reduces the frequency of metabolic decompensations, can liberalise protein intake and improve quality of life and should continue to be considered in selected cases.